Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Fig. 2

Effect of ASK120067 on cancer cells harboring mutant or wild-type EGFR. a and b ASK120067 or osimertinib inhibited the phosphorylation of EGFR at Tyrosine residue 1068 and its downstream signaling proteins AKT and ERK in NCI-H1975 cells (EGFR L858R/T790M) a while showing less activity against the activation of EGFR and its downstream signaling in A431 cells expressing EGFR WTb. c Apoptosis of NCI-H1975 cells was evaluated by flow cytometry after treatment with increasing concentrations of ASK120067 for 24 to 72 h. Data are plotted as the mean ± SEM, and significance of differences was determined by Student’s t test (∗p < 0.05, ∗∗p < 0.01). d The expression levels of cleaved PARP and cleaved caspase-3 in NCI-H1975 cells after ASK120067 treatment were determined by Western blot analysis

Back to article page

Molecular Cancer

ISSN: 1476-4598